Observational study / 2016
Edible marijuana exposures reported to US poison centers increased from 2013 to 2015, with drowsiness, tachycardia, and rare intubations documented.
Researchers analyzed 430 single-substance human exposure calls regarding edible marijuana products reported to the US National Poison Data System from January 2013 to December 2015. Calls increased each year, with the highest numbers in Colorado (n=166) and Washington (n=96), and 91% occurring in states with decriminalized medical/recreational marijuana. The most common age groups were ≤5 years (n=109) and 13–19 years (n=78). Frequent clinical effects included drowsiness/lethargy (43%), tachycardia (31%), agitation/irritability (14%), and confusion (14%). Common therapies included intravenous fluids (20%), dilute/irrigate/wash (11%), and benzodiazepines (11%). Three patients (ages 4, 10, and 57 years) required intubation, while no deaths were reported.
Shows an association, not proof of cause and effect.
- Study type
- Retrospective poison center registry analysis
- Who was studied
- 430 single-substance human exposure calls related to edible marijuana products
- What was measured
- Clinical effects, therapies administered, and level of healthcare utilization
THE PAPER
Characterization of edible marijuana product exposures reported to United States poison centers.
Cao D, Srisuma S, Bronstein AC, Hoyte CO. Clin Toxicol (Phila), 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.